ClinicalTrials.gg
Enrolling by invitationNCT00623116Updated Feb 25, 2008

A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland

An interventional study of Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below) in Kallmann Syndrome, sponsored by Hospital for Children and Adolescents, Finland. Enrolling by invitation at 1 site in Finland. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-02-25.

Sponsored by Hospital for Children and Adolescents, Finland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2012, 13 years 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
15 Years and older
Sex
All
01

Study summary

Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.

Read the detailed description

Kallmann syndrome is comprised of idiopathic hypogonadotropic hypogonadism and anosmia (inability to smell). Associated phenotypes may include cryptorchidism, microphallus, bone deformations, mirror movements, hearing loss and infertility. Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.

02

Conditions studied

  • Kallmann Syndrome

Keywords

  • Kallmann Syndrome
  • hypogonadotropic hypogonadism
03

In context

Kallmann Syndrome

23 studies on the registry are indexed under Kallmann Syndrome; 5 are open to participants now.

This study's planned enrollment of 50 is below the median of 75 across 14 interventional studies indexed under Kallmann Syndrome.

Browse Kallmann Syndrome studies →

Lead sponsor

Hospital for Children and Adolescents, Finland is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Kallmann syndrome
  • Age 15 yrs or more

Exclusion criteria

Exclusion Criteria:

  • Severe mental retardation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Interventions

  • DrugShort withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)

    clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.

06

What researchers measure

Primary outcomes

  1. Clinical features including quality of life, reversibility and genetic features of Kallmann syndrome in Finland

    Time frame: 0, 3 mo and during subsequent F/U

Secondary outcomes

  1. epidemiology

    Time frame: by 2012 (anticipated)

07

Study locations

1 site
  • Hospital for Children and Adolescents, Helsinki University Central Hospital
    Helsinki, 00029 HUCH, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2012 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2008
First posted
Feb 25, 2008
Start
Dec 2007
Primary completionEst.
Dec 2012
CompletionEst.
Dec 2025
Last update
Feb 25, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00623116
Lead sponsor
Hospital for Children and Adolescents, Finland
First posted
Feb 25, 2008
Start date
Dec 2007
Primary completion
Dec 2012 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 25, 2008

Study contacts

Taneli J Raivio, MD PhD
study director · Hospital for Children and Adolescents, Helsinki University Central Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion